UF Health Cancer Center | Strategic Alliance Partners
The University of Florida Health Cancer Center stands alone in the state of Florida in its unique ability to blend comprehensive patient care and innovative research in a collaborative, multidisciplinary environment. It boasts a membership of more than 300 researchers and clinicians from across the University of Florida and UF Health, the Southeast’s most comprehensive academic health center on the main campus of one of the nation’s top five public research universities. The Cancer Center is dedicated to providing leading-edge cancer care and conducting original research to prevent, detect, treat and ultimately cure cancer while addressing the unique challenges of the cancer burden faced by the population we serve. UF Health includes more than 30,000 faculty and staff and manages more than 3 million inpatient and outpatient visits each year by leveraging three not-for-profit hospital systems — UF Health Shands, UF Health Jacksonville and UF Health Central Florida — that include 10 hospitals. In 2023, the center became the 72nd NCI-Designated Cancer Center and the only one based at a public university in the state of Florida.
Latest from UF Health Cancer Center
Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith
December 10th 2024S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.
Dr Hitchcock on the Rationale for the ERAsur Trial in Limited mCRC
June 15th 2023Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.
Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian Cancer
April 5th 2023Burak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.
Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold Tumors
March 1st 2023Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.
Traveling Through the Lung Cancer Treatment Paradigm: Managing irAEs With Corticosteroids
March 1st 2023In this fourth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the management of immune-related adverse effects and the goal of mitigating steroid use for patients with lung cancer.
Traveling Through the Lung Cancer Treatment Paradigm: Taking Advantage of Neoadjuvant Therapy
February 22nd 2023In this third episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the expanding role of neoadjuvant therapy in non–small cell lung cancer and efforts to better identify patients who can benefit from curative-intent treatment.
Traveling Through the Lung Cancer Treatment Paradigm: Biomarker Guidance in NSCLC
February 15th 2023In this second episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the need for additional circulating biomarkers beyond PD-L1 in non–small cell lung cancer.
Pembrolizumab Plus Total Neoadjuvant Therapy Improves Long-Term OS in Locally Advanced Rectal Cancer
Thomas J. George, MD, FACP, highlights the long-term data from the NRG-GI002 trial, the next steps for exploring subsets of patients who may benefit from the addition of pembrolizumab or veliparib to total neoadjuvant therapy, and what the use of total neoadjuvant therapy has meant for patients with stage II/III locally advanced rectal cancer.
